Telix and Varian Collaboration to Combine Theranostics with EBRT
Thursday, December 11, 2025
Telix has announced a new clinical collaboration with Varian.
The partnership aims to develop new clinical approaches that bring together Telix’s theranostic products with external beam radiation therapy (EBRT).
EBRT is a well-established treatment used for many solid tumours and is delivered by radiation oncologists who guide patients through different stages of cancer care. Telix and Varian plan to explore how integrating therapeutic radiopharmaceuticals and precision imaging could support better patient selection and more targeted treatment within radiation oncology.
The first area of investigation focuses on prostate cancer. The companies will assess how PSMA-PET imaging and Telix products such as Gozellix® and Illuccix® could help identify suitable patients for EBRT, support personalised treatment planning, including adaptive radiotherapy, and monitor treatment outcomes. The collaboration includes both company-sponsored and investigator-led studies to encourage extensive clinical evaluation.
Although the initial work centres on PSMA imaging, the agreement provides a broader framework for future joint development. This could involve other PET imaging candidates in Telix’s pipeline, including TLX250-CDx (Zircaix®) and TLX101-CDx (Pixclara®), along with potential therapeutic radiopharmaceuticals. The companies believe that combining radiopharmaceutical theranostics with Varian’s EBRT technology could strengthen the role of radiation oncologists in both definitive and palliative cancer treatment.
The collaboration is expected to support the long-term development of more precise, patient-focused cancer care by aligning molecular imaging with advanced radiation therapy.
Source: telixpharma.com
